BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
90.17
+11.84 (15.12%)
At close: Jul 9, 2026, 4:00 PM EDT
90.24
+0.07 (0.08%)
After-hours: Jul 9, 2026, 6:09 PM EDT
BridgeBio Pharma Market Cap
BridgeBio Pharma has a market cap or net worth of $17.68 billion as of July 9, 2026. Its market cap has increased by 109.43% in one year.
Market Cap
17.68B
Enterprise Value
19.38B
1-Year Change
109.43%
Ranking
Category
Stock Price
$90.17
Market Cap Chart
Since June 27, 2019, BridgeBio Pharma's market cap has increased from $3.32B to $17.68B, an increase of 432.47%. That is a compound annual growth rate of 26.82%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jul 9, 2026 | 17.68B | 19.92% |
| Dec 31, 2025 | 14.74B | 184.24% |
| Dec 31, 2024 | 5.19B | -26.16% |
| Dec 29, 2023 | 7.02B | 516.56% |
| Dec 30, 2022 | 1.14B | -53.61% |
| Dec 31, 2021 | 2.46B | -71.83% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 27, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Genmab | 17.14B |
| Ascendis Pharma | 16.64B |
| Jazz Pharmaceuticals | 15.34B |
| Exelixis | 13.96B |
| Ionis Pharmaceuticals | 13.75B |
| ABIVAX Société Anonyme | 12.69B |
| Axsome Therapeutics | 12.48B |
| Summit Therapeutics | 12.36B |